Andreas Hagen Røssevold PhD defense

Eide HA, Grut H, Jebsen P, Kyte JA, Bratland Å (2026)
Hyperfractionated reirradiation and PD-1 blockade in recurrent squamous cell head and neck carcinomas with poor prognosis, results from the REPORT-trial
Radiother Oncol, 219, 111514 (in press)
DOI 10.1016/j.radonc.2026.111514, PubMed 41916446

Svalheim KG, Andresen NK, Bjerre C, Gilje B, Jakobsen EH, Falk RS, Naume B, Kaasa S, Kyte JA (2026)
Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer
Breast, 86, 104704
DOI 10.1016/j.breast.2026.104704, PubMed 41581361

Ullern A, Holm K, Andresen NK, Røssevold AH, Bang C, Naume B, Hov JR, Kyte JA (2025)
Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy
Mol Oncol, 20 (2), 511-523
DOI 10.1002/1878-0261.70117, PubMed 40852937